Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences | London | £74.63B | 93.1x | -1.15 | £59.87 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Adobe | London | £190.22B | 50.3x | 8.12 | £427.78 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
London Stock Exchange | London | Financial | Investment Banking & Investment Services | £53.96B | 81.2x | -2.08 | £101.80 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.6% Upside | Upgrade to Pro+ | |
Ferrovial | London | Industrials | Construction & Engineering | £23.09B | 35.4x | 0.16 | £31.72 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | London | Healthcare | Pharmaceuticals | £180.29B | 14.9x | 0.2 | £89.51 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Investor AB | London | Financial | Investment Holding Companies | £66.47B | 4.5x | 0.1 | £13.99 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | London | Healthcare | Pharmaceuticals | £196.11B | 39.9x | 9.37 | £126.50 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.4% Upside | Upgrade to Pro+ | |
Eli Lilly and Co | London | Healthcare | Pharmaceuticals | 111.1x | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||||
Booking | London | Consumer Cyclicals | Hotels & Entertainment Services | £95.25B | 25.7x | 1.06 | £2,844.85 | 41.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eiffage SA | London | Industrials | Construction & Engineering | £7.72B | 9.2x | 1.15 | £80.66 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ashtead Group | London | Industrials | Professional & Commercial Services | £22.65B | 19.1x | -2.94 | £51.90 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.3% Upside | Upgrade to Pro+ | |
Merck & Co Inc | London | Healthcare | Pharmaceuticals | £227.44B | 21.8x | 0.06 | £90.76 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk L | London | Healthcare | Pharmaceuticals | £442.40B | 44.3x | 1.25 | £100.61 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
NVIDIA | London | £1.92T | 48x | 0.12 | £78.67 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
BHP Group PLC | London | Basic Materials | Metals & Mining | £99.08B | 16.4x | -0.42 | £19.52 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.3% Upside | Upgrade to Pro+ |